novartis ceo: spinoffs will see us succeed as a pure-play innovative medicines company
Published 11 months ago • 344 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
0:45
novartis ceo: company set to become a pure play, innovative medicine business after sandoz spin off
-
4:17
novartis transformation into a pure-play innovative medicines company
-
3:29
novartis generated $40 billion in innovative medicine sales, says ceo
-
0:54
novartis as a focused innovative medicines company
-
1:58
novartis raises outlook after sandoz generics spinoff
-
4:43
novartis ceo: our leukemia drug scemblix is a potential $3 billion plus medicine
-
6:12
novartis ceo: expect continued growth in 2023
-
15:24
fee % - bsv's endgame utility success metric
-
14:53
took a hard decision to focus on 4 therapeutic areas: novartis ceo | exclusive | cnbc tv18
-
26:06
looking for a better owner for our india-listed biz: novartis ceo | exclusive | global dialogues
-
4:16
novartis ceo vas narasimhan: our medicines are starting to take market share and deliver on promises
-
4:37
novartis positioning is now best-suited for long-term gains and returns after spin-off, says ceo
-
4:54
novartis ceo: confident about continued sales growth for rest of year
-
7:51
watch cnbc's full interview with novartis ceo vas narasimhan
-
3:29
innovative medicines business returning to growth, novartis ceo says
-
12:38
health care in a post-pandemic world with vas narasimhan novartis at cnbc evolve global summit 2021
-
3:43
novartis ceo vas narasimhan on the latest research on a breast cancer drug
-
1:51
committed to growing over 4% through 2026, says novartis ceo
-
2:05
ceo of swiss drugmaker novartis outlines some major industry trends for 2024
-
11:50
novartis ‘focusing on high-end, innovative medicines,’ ceo says
-
4:17
novartis ceo: we expect our six key drugs to grow ahead of analyst expectations
-
7:01
novartis ceo: nations pulling back on health care spending ‘has long-term consequences'